The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.

Authors

Ramon Salazar

Ramon Salazar

Institut Catala d'Oncologia, Barcelona, Spain

Ramon Salazar , Jan Willem de Waard , Bengt Glimelius , John Marshall , Joost Klaase , Jacobus Van Der Hoeven , Jaume Capdevila , Frédéric Bibeau , Lisette Stork-Sloots , Robert Rosenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00903565

Citation

J Clin Oncol 30, 2012 (suppl 4; abstr 678)

DOI

10.1200/jco.2012.30.4_suppl.678

Abstract #

678

Poster Bd #

G15

Abstract Disclosures

Similar Posters

First Author: Ramon Salazar

First Author: Ramon Salazar

First Author: R. Salazar

Poster

2014 ASCO Annual Meeting

Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.

Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.

First Author: Ramon Salazar